ArticleCommunications biology2025
Astragalin promotes HSCs ferroptosis through NCOA4 mediated ferritinophagy to alleviate liver fibrosis in zebrafish and mice.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Palmitic Acid-Induced Hepatotoxicity in Adult Zebrafish: Molecular Mechanisms and Advances in Intervention.Biology · 2026Review
- Ginsenosides: potential therapeutic agents against hepatic fibrosis.Journal of ginseng research · 2026Review
- A fistful of iron: ferritin as a vulnerability point of the brain cancers.Cell death & disease · 2026Review
- Vitamin C protects oligodendrocyte lineage cells and modulates microglial inflammation during OGD/R in vitro.Scientific reports · 2026Article
- Dual Roles of Natural Products in Regulating Ferroptosis in Acute and Chronic Liver Diseases: A Review.Oxidative medicine and cellular longevity · 2026Review
- Nanomedicine-Driven Modulation of Signaling Pathways in Hepatic Fibrosis.International journal of nanomedicine · 2026Review
- Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Liver fibrosis is pathological progression of chronic liver disease. Recent research has focused on the activation of hepatic stellate cells (HSCs), highlighting their potential as targets for mitigating fibrosis. While herbal medicines and natural active ingredients have shown promising anti-fibrotic effects in clinical treatments, the impact of Astragalin (Ag) remains unexplored. In this study, we established in vivo and in vitro studies, employing fluorescence probe staining, transmission electron microscopy, and various analytical techniques. The results demonstrated Ag operates within a wide range of safe therapeutic doses in zebrafish and effectively alleviates liver fibrosis. Further experiments demonstrated that Ag induced HSCs ferroptosis via this pathway, leading to iron overload and ultimately alleviating liver fibrosis. In general, this study demonstrated that Ag promotes HSCs ferroptosis through NCOA4-mediated ferritinophagy, clarifying its mechanism in treating liver fibrosis and positioning Ag as a promising candidate for future clinical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.